As enrollment for Medicare Advantage begins this month, older Americans are confronting fewer options because insurers are discontinuing coverage in many areas.
Category: Drugs (Pharmaceuticals)
-
Private Medicare Plans Are Raising Costs And Forcing Millions To Find New Insurance
The New York Times – Business: -
America Wants to Make More Generic Drugs. India Shows Why That’s Hard.
The New York Times – Business:Cheap labor and global supply chains are among the obstacles to President Trump’s plan to bring generic drug manufacturing back home.
-
A.I. Is ‘Better Informed’ Than Doctors, Kennedy Tells Industry-Backed MAHA Summit
The New York Times – Business:The health secretary, Vice President JD Vance and other top officials addressed a conference sponsored by corporations, including A.I. companies and others with business before the government.
-
Have GLP-1 Drugs Changed How You Travel? Tell Us About It.
The New York Times – Travel:The New York Times wants to know how a GLP-1 medication may have affected how readers plan vacations.
-
Trump Promotes Program to Reduce Medicaid Drug Prices
The New York Times – Business:Ahead of the midterm elections, the president said that all states had opted in to an effort to align Medicaid’s prices for medicines with those in other wealthy countries.
-
Use of GLP-1s Like Ozempic Is Forcing Food Companies to Adapt
The New York Times – Business:People on medications for weight loss are buying less food, shrinking their portion sizes and purchasing smaller clothes. Businesses are trying to adjust.
-
The Heart Drug Pelacarsen Fails, Shocking Novartis and Cardiologists
The New York Times – Business:Doctors were hopeful the drug, which was being tested in a large clinical trial by Novartis, was going to be a powerful new tool to fight heart disease.
-
Ozempic Maker Novo Nordisk’s Investors Are Nervously Looking Into the Future
The New York Times – Business:Novo Nordisk’s chief executive, Mike Doustdar, is a year into a corporate turnaround. He says investors are still underestimating the promise of the company’s drugs.
-
A $480,000-a-Year Pill Reflects a New Normal for Cancer Drugs
The New York Times – Business:Rasonque, the new pancreatic cancer treatment from Revolution Medicines, illustrates the huge inflation in cancer drug prices over the past two decades.
-
Walmart to Pay $50 Million to Settle Opioid Lawsuit, US Says
The New York Times – Business:The resolution is part of an effort to hold retailers and pharmacists accountable for what the government says were their roles in the opioid epidemic.
-
New Drug Approved by F.D.A. for Pancreatic Cancer Could Be First of Many
The New York Times – Business:Companies are testing dozens of similar drugs in cancers of the pancreas, lung, colon and more.
-
F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer
The New York Times – Business:In a key clinical trial, patients who got the pill, daraxonrasib, lived twice as long as those who got chemotherapy.